$7.01M
1
8
$7.01M
1
8
Trader mode: Actionable analysis for identifying opportunities and edge
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026 according to the CDC case counter between January 1, 2026, 12:00 AM ET and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution tim
Prediction markets estimate a 96% chance that the United States will see at least 1,000 confirmed measles cases in 2026. In simpler terms, traders see this outcome as almost certain. This reflects a strong consensus that the recent surge in measles outbreaks is not a temporary spike but a trend that will continue into next year.
Two main factors are driving this near-certain prediction. First, vaccination rates have fallen. The share of U.S. kindergarteners with the two-dose MMR vaccine has dipped below 95%, the level needed for herd immunity, for three consecutive years. This creates pockets of vulnerable populations where the highly contagious virus can spread quickly.
Second, the current year provides a clear benchmark. The U.S. has already reported over 1,500 measles cases in 2024, the highest annual total in decades. Markets are betting that the conditions causing this surge, primarily lower vaccination coverage, will not reverse in time to prevent another high-case year in 2026.
The most important signals will be vaccination data and early outbreak patterns. Watch for the CDC's annual report on kindergarten vaccination coverage, typically released in late 2024, which will show if coverage gaps are widening or stabilizing. Major localized outbreaks in the spring or fall of 2025 would also strongly indicate continued risk for 2026. Finally, any new state or federal policies designed to increase childhood vaccination rates could shift predictions if they are seen as effective.
Prediction markets are generally reliable for forecasting outcomes tied to clear public data, like disease case counts. They effectively aggregate diverse information about public health trends. However, the 96% probability should not be seen as a guarantee. An unprecedented public health campaign to boost vaccinations or simply milder outbreak luck could lead to fewer than 1,000 cases. The market's extreme confidence mostly tells us that traders see no evidence such a turnaround is on the horizon.
Prediction markets assign a 96% probability that the United States will record at least 1,000 measles cases in 2026. This price, trading at 96¢ for "Yes" on Polymarket, signals near-certainty among traders. With over $7 million in total volume across related markets, this is a highly liquid and confident bet on a significant outbreak. A 96% chance means the market views this outcome as almost inevitable, with minimal perceived risk of case counts staying below the threshold.
Two primary trends justify this extreme market confidence. First, U.S. measles cases are already surging. The CDC reported 338 cases in 2024, the highest annual total since 2019, driven by multiple localized outbreaks. This established upward trajectory makes a jump to 1,000 cases in 2026 a logical projection. Second, vaccination coverage has declined. National MMR vaccination rates for kindergarteners have fallen to 93.1%, below the 95% threshold needed for herd immunity. This creates persistent vulnerability in communities across the country, allowing imported cases to spark larger, sustained outbreaks.
The current 96% price leaves little room for error, but two developments could shift it. A successful, large-scale public health campaign in 2025 to boost childhood vaccination rates in high-risk counties could potentially reduce the susceptible population and lower projected case counts. Conversely, the market may be underestimating the potential for an explosive, single outbreak. The 2019 outbreak in New York exceeded 1,200 cases alone. A similar event in a major metropolitan area with low vaccination rates could cause cases to far exceed 1,000, but the market already prices this high baseline risk. The next major data point will be the CDC's final case count for 2024, published in early 2025, which will set the benchmark for 2026 projections.
AI-generated analysis based on market data. Not financial advice.
This prediction market topic concerns whether the United States will record a specified number of confirmed measles cases in 2026. Measles, also known as rubeola, is a highly contagious viral disease that was declared eliminated in the U.S. in 2000. The market resolves based on data from the Centers for Disease Control and Prevention (CDC) case counter, which tracks laboratory-confirmed infections reported by state health departments. Interest in this topic stems from a significant resurgence of measles in recent years, driven largely by declining vaccination rates in certain communities. This trend has reversed decades of progress and reintroduced a preventable disease as a public health threat. The annual case count is now a key indicator of the effectiveness of vaccination programs and public health infrastructure. Observers monitor these numbers to gauge the risk of sustained domestic transmission re-establishing itself, which would represent a major setback for American disease control efforts.
Measles was a common childhood illness in the U.S. before a vaccine was introduced in 1963, causing an estimated 3 to 4 million cases and 400 to 500 deaths annually. A major public health achievement occurred in 2000 when the CDC declared measles eliminated, meaning no continuous disease transmission for over 12 months. This success was attributed to high population immunity achieved through the two-dose MMR vaccine regimen, which is about 97% effective. The modern era of measles resurgence began around 2014, with several large outbreaks linked to international travel and under-vaccinated communities. A pivotal event was the 2014-2015 Disneyland outbreak in California, which infected 147 people and prompted legislative efforts to remove non-medical vaccine exemptions. The largest outbreak in the post-elimination era occurred in 2019, with 1,274 confirmed cases across 31 states, primarily in close-knit communities with low vaccination rates. This demonstrated the fragility of elimination status when vaccination coverage wanes.
Measles outbreaks impose direct economic costs on healthcare systems and families, including medical expenses, lost productivity, and costly public health containment efforts. A 2015 study in Vaccine estimated the economic burden of a single measles case at over $20,000 when accounting for outbreak response. Politically, case numbers influence legislation on school vaccine mandates and exemption policies, with at least 15 states tightening their laws since 2019. High case counts can erode public trust in health authorities and scientific institutions, potentially reducing compliance with recommendations for other vaccines. Measles also functions as an early warning system. Because it is so contagious, a rise in cases often signals gaps in the public health safety net that could allow other vaccine-preventable diseases to spread. Outbreaks disproportionately affect children too young for vaccination, immunocompromised individuals, and communities with limited healthcare access.
As of late 2024, the U.S. is experiencing its largest measles resurgence in five years. Multiple outbreaks are ongoing, including significant clusters in Ohio, Pennsylvania, and Florida. Public health officials attribute the rise to a combination of factors: a rebound in international travel post-pandemic, declining childhood vaccination rates, and increased vaccine hesitancy. The CDC has issued several health advisories to clinicians, urging heightened suspicion for measles and prompt reporting. Several local health departments have implemented exclusion policies for unvaccinated students exposed to the virus.
The CDC relies on reports from state health departments, which require a case to meet a clinical definition and have laboratory confirmation. Confirmation typically involves a positive PCR test or the presence of measles-specific IgM antibodies. The national count is updated weekly on the CDC website.
Measles (rubeola) and rubella are caused by different viruses. Measles is more severe, with higher fever and a distinct rash. Rubella is generally milder but poses a severe risk to pregnant women, causing congenital rubella syndrome. Both are prevented by the MMR vaccine.
Two doses of the MMR vaccine are about 97% effective at preventing measles. Vaccine-induced immunity is very durable for most people, but a very small percentage of vaccinated individuals may not develop full protection. Breakthrough infections in vaccinated people are usually milder.
Common complications include ear infections and diarrhea. More severe outcomes are pneumonia, which is the cause of most measles-related deaths, and encephalitis (brain swelling). A rare but fatal late complication, subacute sclerosing panencephalitis (SSPE), can develop 7 to 10 years after infection.
Outbreaks cluster in communities where vaccination coverage falls below the 95% herd immunity threshold. This can occur in geographically isolated areas, in groups with religious or philosophical objections to vaccination, or in communities targeted by misinformation campaigns. Close contact within these groups facilitates rapid spread.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
8 markets tracked
No data available
| Market | Platform | Price |
|---|---|---|
| Poly | 96% |
| Poly | 75% |
| Poly | 68% |
| Poly | 63% |
| Poly | 53% |
| Poly | 30% |
| Poly | 20% |
| Poly | 18% |
No related news found
Add this market to your website
<iframe src="https://predictpedia.com/embed/QcEuMv" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="Measles cases in U.S. in 2026?"></iframe>